Edition:
India

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

5.38USD
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
$5.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
263,453
52-wk High
$21.15
52-wk Low
$2.80

Summary

Name Age Since Current Position

Jay Lichter

55 2015 Independent Chairman of the Board

David Weber

57 President, Chief Executive Officer, Director

Paul Cayer

55 2015 Chief Financial and Business Officer

Robert Savel

49 2014 Chief Technical Officer

Kathie Bishop

51 2017 Chief Scientific Officer

Eric Loumeau

54 2015 Chief Compliance Officer, General Counsel, Secretary

Dean Hakanson

65 2015 Chief Medical Officer

Vickie Capps

55 2014 Independent Director

Iain McGill

44 2016 Independent Director

George Morrow

65 2015 Independent Director

Heather Preston

51 Independent Director

Theodore Schroeder

62 2015 Independent Director

Biographies

Name Description

Jay Lichter

Dr. Jay Lichter, Ph.D. is Independent Chairman of the Board of the Company. He served as our Chief Executive Officer from inception until November 2010. He is an experienced biotechnology and pharmaceutical business executive with 25 years of experience in management, scientific research and business development. Since 2007, Dr. Lichter has been a managing director at Avalon Ventures, an early-stage venture capital fund focused on information technology and life sciences. In that role, he led Avalon’s investments in and served as a director and chief executive officer for privately-held biotechnology companies Afraxis, Inc., Carolus Therapeutics, Inc., ReVision Therapeutics, Inc. and Zacharon Pharmaceuticals, Inc. Dr. Lichter also led Avalon’s investments in or serves on the board of privately-held companies Fortis Therapeutics, T-Rx, AristaMD, SynthoRx, Sova Pharmaceuticals, Inc., Avelas Biosciences, Inc., COI Pharmaceuticals Inc. and Sitari Pharmaceuticals Corp. He previously served on the board of directors of Aratana Therapeutics, Inc., a public company, until August 2015. Dr. Lichter received a Bachelor’s degree and Ph.D. in biochemistry from the University of Illinois. He also completed post-doctoral fellowships at Yale University and Du Pont Merck Pharmaceutical Company.

David Weber

Dr. David A. Weber, Ph.D. is President, Chief Executive Officer, Director of the Company. Prior to joining, Dr. Weber served from February 2004 to April 2010 as the Chief Executive Officer of MacuSight, Inc., a developer of a sustained delivery formulation of sirolimus for the treatment of severe ophthalmic diseases. Prior to MacuSight, Dr. Weber served as acting Chief Executive Officer and Executive Vice President of Oculex Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of intraocular pharmaceuticals and drug delivery systems, until its acquisition by Allergan in 2003. Dr. Weber has also held management positions with Oral-B Laboratories, a developer and manufacturer of oral hygiene products, and with Procter & Gamble, Co., a consumer products company. Dr. Weber earned his Ph.D. in medical microbiology from Creighton University and his Master’s and Bachelor’s degrees in biological sciences from Wichita State University.

Paul Cayer

Mr. Paul E. Cayer is Chief Financial and Business Officer of the Company. He served as our Chief Business Officer since October 2008, Chief Financial Officer since October 2010, and served as our Secretary from February 2011 until July 2015. Mr. Cayer brings more than 25 years of experience in the pharmaceutical, medical device and healthcare technology field. Prior to joining our company, Mr. Cayer served from 2005 to 2008 as Senior Vice President, Corporate Development for Verus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of allergic and respiratory disorders in children. From 2001 to 2005, Mr. Cayer served as the Chief Financial Officer and Senior Vice President, Business Development of Targeted Molecules Corporation, a biopharmaceutical company. Mr. Cayer has also held various management positions with Gensia Pharmaceuticals, Inc., a biopharmaceutical company, Acuson, a provider of medical ultrasound systems, Castle & Cooke, a consumer products company, and served as consultant with Booz-Allen & Hamilton, a management and technology consulting firm. Mr. Cayer received his MBA and Bachelor’s degree in biomechanical engineering from Harvard University.

Robert Savel

Mr. Robert Michael Savel, II serves as Chief Technical Officer of the Company. From September 2011 to December 2013, Mr. Savel served as General Manager and Senior Vice President of Operations for Optimer Pharmaceuticals, Inc., a biopharmaceuticals company. From September 2010 to June 2011, Mr. Savel served as Senior Vice President and Chief Technical Officer for Inspire Pharmaceuticals, Inc., an ophthalmic pharmaceutical company. From April 2008 to September 2010, Mr. Savel served as President of Savel Enterprises LLC, a management consulting firm. From April 2007 to April 2008, Mr. Savel served as the Senior Vice President of Technical Operations for PDL BioPharma, an antibody manufacturer. Earlier in his career, he held leadership operating positions with Johnson & Johnson, a medical devices, pharmaceutical and consumer packaged goods manufacturer, which included the position of Vice President, Quality and Compliance. Mr. Savel holds Bachelor’s degree in mechanical engineering from Virginia Polytechnic Institute and State University in Blacksburg, Virginia.

Kathie Bishop

Dr. Kathie M. Bishop, Ph.D. is Chief Scientific Officer of the Company. From 2015 to 2016, Dr. Bishop served as Chief Scientific Officer at Tioga Pharmaceuticals, Inc., a biotechnology company. From 2009 to 2015, Dr. Bishop served in various positions at Ionis Pharmaceuticals, Inc., a biotechnology company, including as Vice President, Clinical Development and as Executive Director, Clinical Development. From 2001 to 2009, Dr. Bishop served as Director, Research and Development at Ceregene Inc., a biotechnology company. Dr. Bishop currently serves as a Scientific Advisor for the Spinal Muscular Atrophy Foundation and as a Scientific Advisory Board Member of the Myotonic Dystrophy Foundation. Dr. Bishop received her Bachelor’s degree in genetics from the University of British Columbia, Bachelor’s degree in psychology from Simon Fraser University and Ph.D. in neuroscience from the University of Alberta.

Eric Loumeau

Mr. Eric J. Loumeau is Chief Compliance Officer, General Counsel, Secretary of the Company. From December 2013 to May 2015, Mr. Loumeau served as Vice President of Legal Affairs at The Medicines Company, a global biopharmaceutical company. From June 2011 to December 2013, Mr. Loumeau served as Vice President, Chief Financial Officer and Chief Compliance Officer of Rempex Pharmaceuticals, Inc., a pharmaceutical company. From January to June 2011, Mr. Loumeau served as a legal and financial consultant at Mpex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company. From January 2009 to January 2011, Mr. Loumeau was Partner at Bass, Berry & Sims, PLC, a law firm. From May 2007 to January 2009, Mr. Loumeau was Partner at Mintz Levin Cohn Ferris Glovsky and Popeo PC, a law firm. From October 1999 to May 2007, Mr. Loumeau served as General Counsel and Chief Compliance Officer for Hollis-Eden Pharmaceuticals, a publicly traded biotechnology company. Earlier in his career he was Partner and Associate at the law firm Cooley LLP and Associate at the law firm Skadden, Arps, Slate, Meagher & Flom LLP. Mr. Loumeau received his Bachelor’s degree in finance from Brigham Young University and a Juris Doctor from Boalt Hall School of Law at the University of California, Berkeley.

Dean Hakanson

Mr. Dean Hakanson, M.D. is Chief Medical Officer of the Company. From May 2010 to March 2015, Dr. Hakanson served as Vice President and Head of Health Economics and Outcomes Research for U.S. Medical and Regulatory Affairs, and from July 2009 to May 2010 as Vice President and Medical Head of the Western U.S. Operating Unit, for Novartis AG, a pharmaceutical company. From January 2008 to July 2009, Dr. Hakanson served as Vice President of Healthcare Access for Bristol-Myers Squibb Company, a manufacturer of prescription pharmaceuticals. From June 2005 to January 2008, Dr. Hakanson served as Head of Value-Based Health Care/Payer Field Team for Genentech, Inc., a biotechnology corporation which is now a division of F. Hoffman-La Roche AG. He is also a Fellow with the American Academy of Otolaryngology – Head and Neck Surgery and a Diplomat of the American Board of Anesthesiology, American Medical Association and the American Association for Physician Leadership. Currently he is licensed to practice medicine in California and Arizona. Dr. Hakanson received his Bachelor’s degree in cellular physiology and physics from the University of Denver, a Medical degree from the University of Colorado School of Medicine, anesthesiology residency training at the University of Michigan and training in critical care at the University of California, Davis Medical Center.

Vickie Capps

Ms. Vickie L. Capps is Independent Director of the Company. From August 2014 to December 2015, Ms. Capps served as the Executive Director at Eagle Rx, Inc., a provider of pharmacy services to the hospice industry. From July 2002 to December 2013, Ms. Capps was the Chief Financial Officer of DJO Global, Inc. Ms. Capps joined DJO Global, Inc. in 2002. Prior to joining DJO Global, Inc., Ms. Capps served as the Chief Financial Officer of several other public and private companies. Earlier in her career, Ms. Capps was a Senior Audit and Accounting Professional at Ernst & Young LLP. Ms. Capps is currently a member of the Senior Advisory Board of Consonance Capital Partners, or CCP, a healthcare investment firm, and is a member of the board of directors of CCP’s portfolio company, Eagle Rx, Inc. Ms. Capps is also a member of the board of directors of Connecture, Inc., a health care IT company, and is the chair of its audit committee and a member of its nominating and governance committee. Ms. Capps is also a member of the board of directors and audit committee of NuVasive, Inc., a medical device company. From December 2013 to August 2015, Ms. Capps served as a member of the board of directors of RF Surgical Systems, Inc., a private medical device company, and as chair of its audit committee, prior to the company’s acquisition by Medtronic plc in August 2015. From 2007 to July 2010, Ms. Capps served as a member of the board of directors of SenoRx, Inc., a surgical products company, prior to its acquisition by C. R. Bard, Inc. in July 2010. Ms. Capps is a California Certified Public Accountant and was recognized as CFO of the Year by the San Diego Business Journal in 2009 and 2010. Ms. Capps holds a Bachelor’s degree in Business Administration/Accounting from San Diego State University.

Iain McGill

Mr. Iain R. McGill is Independent Director of the Company. He currently serves as Senior Vice President of Jazz Pharmaceuticals Europe and Rest of World for Jazz Pharmaceuticals Public Limited Company, an international biopharmaceutical company, since March 2015. From March 2014 to March 2015, Mr. McGill served as Head of EUSA Pharma and Senior Vice President, Jazz Pharmaceuticals, and as Chief Commercial Officer, EUSA Pharma, a specialty pharmaceutical company, from June 2012 to March 2014, when he joined Jazz Pharmaceuticals in connection with its acquisition of EUSA Pharma. From October 2011 to June 2012, Mr. McGill served as Chief Commercial Officer at EUSA Pharma (Europe) Ltd. From August 2010 to September 2011, he served as President Europe, International & Global Marketing of EUSA Pharma (Europe) Ltd, and from January 2010 to July 2010, as President of Europe. From 2006 to 2009, Mr. McGill served as Vice President and Global Business Manager at Wyeth, a pharmaceutical company acquired by Pfizer Inc. Mr. McGill holds a Bachelor of Science degree in Biochemistry from the University of London.

George Morrow

Mr. George J. Morrow is Independent Director of the Company. He served as a consultant to Amgen Inc., a global biotechnology company, from February 2011 until January 2013. From 2003 until his retirement in February 2011, he was the Executive Vice President, Global Commercial Operations at Amgen Inc., where he also served as Executive Vice President of Worldwide Sales and Marketing between 2001 and 2003. From 1992 to 2001, Mr. Morrow held multiple leadership positions at GlaxoSmithKline Inc. and its subsidiaries, including President and Chief Executive Officer of Glaxo Wellcome Inc. Mr. Morrow currently serves on the board of directors of public companies Align Technology, Inc., a medical device company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Vical Incorporated, a developer of biopharmaceutical products. Mr. Morrow served on the board of directors of Safeway Inc., a food and drug retailer, from May 2013 to February 2015, when it was acquired by an investor group led by Cerberus Capital Management, L.P. He also served on the board of directors of Human Genome Sciences, Inc., a public biopharmaceutical development company, from March 2011 to August 2012, when it was acquired by GlaxoSmithKline plc. Mr. Morrow received a Bachelor’s degree in chemistry from Southampton College, Long Island University, a Master’s degree in biochemistry from Bryn Mawr College and an MBA from Duke University’s Fuqua School of Business.

Heather Preston

Dr. Heather Preston, M.D. is Independent Director of the Company. She is currently employed as a Partner and Managing Director of TPG Biotech, a biotechnology venture capital firm. Dr. Preston joined TPG in 2005. She currently serves on the board of directors of Alder Biopharmaceuticals, Inc., a public company and on the boards of a number of private companies. Prior to joining TPG Biotech, Dr. Preston served for two years as a medical device and biotechnology venture capital investor at JP Morgan Partners, LLC, a private equity firm. Prior to that, she was an Entrepreneur-in-Residence at New Enterprise Associates, a venture capital firm. From 1997 to 2002, Dr. Preston served as a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co. in New York. Dr. Preston holds a Bachelor’s degree in biochemistry from the University of London and an MD from the University of Oxford. After leaving Oxford, Dr. Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University. Dr. Preston completed her training in Internal Medicine at the Massachusetts General Hospital and then sub-specialized in Gastroenterology and Hepatology at U.C.S.F. During Dr. Preston’s academic career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award.

Theodore Schroeder

Mr. Theodore R. Schroeder is Independent Director of the Company. He has served as President, Chief Executive Officer and as a member of the board of directors of Zavante Therapeutics, Inc., a private biopharmaceutical company. Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc., a formerly-public pharmaceutical company, and served as its President and Chief Executive Officer, and as a member of the board of directors, from May 2004 until its acquisition in March 2014 by Mallinckrodt Pharmaceuticals, Inc. From August 2002 to February 2004, Mr. Schroeder served as Senior Vice President, North American Sales and Marketing, of Elan Pharmaceuticals, Inc., a neuroscience-based pharmaceutical company, and from February 2001 to August 2002, as General Manager of the Hospital Products Business Unit. Prior to joining Elan Pharmaceuticals, Inc., Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder currently serves on the board of directors of Cidara Therapeutics, Inc, a public biotechnology company. Mr. Schroeder also currently serves on the board of directors of Collegium Pharmaceuticals, a specialty pharmaceutical company, and Biocom, a regional life science trade association, where he is a member of the executive committee. Mr. Schroeder holds a Bachelor’s degree in management from Rutgers University.

Basic Compensation